Poxel Announces Positive Topline Results for Imeglimin Phase 3 Trial (TIMES 3 36-week) for the Treatment of Type 2 Diabetes in Japan Nov 26, 2019
Poxel Announces Participation at the H.C. Wainwright 3rd Annual NASH Investor Conference Oct 17, 2019